Faculty
Chiou, Shih-Hwa / 邱士華
Institute of Pharmacology
02-2871-2121#7394；02-2871-2121#1277
shchiou@nycu.edu.tw；shchiou@vghtpe.gov.tw
Current Position
Distinguished Professor, Institute of Pharmacology, National Yang Ming Chiao Tung University
Office
Academic Degrees
MD, School of Medicine, National Defense Medical College (1994)
Resident Doctor/ Research Fellow, Department of Ophthalmology, Taipei Veterans General Hospital, Taiwan (1994-1999)
Attending physician, Department of Ophthalmology, Taipei Veterans General Hospital, Taiwan (2000-present)
PhD., Institute of Clinical Medicine, National Yang-Ming University (2002)
PostDoc., City of Hope Hospital, Stem Cell /Bone Marrow Transplant Center, USA (2002)
Experience
Visiting Scientist, Department of Molecular Biochemistry, The Scripps Research Institute, USA (2007)
Professor, Institute of Pharmacology, National Yang-Ming University (2011)
Section Chair, Division of Basic Research, Department of Medical Research, Taipei Veterans General Hospital, Taiwan (2013 to now)
Research Interests
(1) Cellular Reprogramming: Nuclear reprogramming induced by transcription factors is the resetting of epigenetic landmarks; it leads to the global reversion of the somatic epigenomes to an ESC-like state. We recently discovered that Parp1 and PARylation may act as the major regulator of reprogramming processes and maintenance of stem cell pluripotency, and these regulated networks were in part activated by endogenous c-Myc. Further studies on identifying the PARylation complex, Parp1-related posttranslational modifications, and it cellular functions during nuclear reprogramming, pluripotency, and tumorigenicity.
(2) Cancer Stem Cell: The involvement of stemness factors in cancer initiation and progression has drawn much attention. Our current study demsotnrated that miR142-3p directly targeted both IL-6 and HMGA2, inhibiting tumor-initiation property through suppressing the IL-6 paracrine loop and HMGA2/Sox2-stemness signaling. Further studies linking inflammatory cytokines with the epigenetic modification would reveal potential tumorous-autocrine/paracrine circuits and benefit to therapeutic development in malignant cancers, including glioblastoma.
Distinguished Professor, Institute of Pharmacology, National Yang Ming Chiao Tung University
MD, School of Medicine, National Defense Medical College (1994)
Visiting Scientist, Department of Molecular Biochemistry, The Scripps Research Institute, USA (2007)
(1) Cellular Reprogramming: Nuclear reprogramming induced by transcription factors is the resetting of epigenetic landmarks; it leads to the global reversion of the somatic epigenomes to an ESC-like state. We recently discovered that Parp1 and PARylation may act as the major regulator of reprogramming processes and maintenance of stem cell pluripotency, and these regulated networks were in part activated by endogenous c-Myc. Further studies on identifying the PARylation complex, Parp1-related posttranslational modifications, and it cellular functions during nuclear reprogramming, pluripotency, and tumorigenicity.